1. Home
  2. ETV vs STOK Comparison

ETV vs STOK Comparison

Compare ETV & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

ETV

Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

HOLD

Current Price

$14.14

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$28.59

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETV
STOK
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ETV
STOK
Price
$14.14
$28.59
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$34.50
AVG Volume (30 Days)
252.5K
812.5K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
8.75%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.68
Revenue
N/A
$205,632,000.00
Revenue This Year
N/A
$430.24
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$41.92
Revenue Growth
N/A
1128.17
52 Week Low
$11.05
$5.35
52 Week High
$13.50
$38.69

Technical Indicators

Market Signals
Indicator
ETV
STOK
Relative Strength Index (RSI) 37.61 40.11
Support Level $14.39 $25.21
Resistance Level $14.64 $31.70
Average True Range (ATR) 0.13 2.09
MACD -0.03 -0.58
Stochastic Oscillator 2.14 27.86

Price Performance

Historical Comparison
ETV
STOK

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: